Label: FEMLYV- norethindrone acetate/ethinyl estradiol kit

  • NDC Code(s): 72495-601-28, 72495-601-84
  • Packager: Millicent US, Inc.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Drug Application

Drug Label Information

Updated July 31, 2024

If you are a consumer or patient please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use FEMLYV™ safely and effectively. See full prescribing information for FEMLYV. FEMLYV (norethindrone acetate and ethinyl estradiol ...
  • Table of Contents
    Table of Contents
  • BOXED WARNING (What is this?)

    WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS

    Cigarette smoking increases the risk of serious cardiovascular events from combined oral contraceptive (COC) use. This risk increases with age, particularly in females over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including FEMLYV, are contraindicated in females who are over 35 years of age and smoke [see Contraindications (4) and Warnings & Precautions (5.1)].

    Close
  • 1 INDICATIONS AND USAGE
    FEMLYV is indicated for use by females of reproductive potential to prevent pregnancy [see Clinical Studies (14)]. Limitations of Use - The efficacy of FEMLYV in females with a body mass index ...
  • 2 DOSAGE AND ADMINISTRATION
    2.1 Dosing FEMLYV - To achieve maximum contraceptive effectiveness, take one ODT every day at about the same time each day. Place one ODT on the tongue, allow to disintegrate and then follow ...
  • 3 DOSAGE FORMS AND STRENGTHS
    Orally disintegrating tablets: • 1 mg norethindrone acetate and 0.02 mg ethinyl estradiol, green, round ODTs, imprinted with “M” on one side and “312” on the other side - • White, round, inert ...
  • 4 CONTRAINDICATIONS
    FEMLYV is contraindicated in females who are known to have or develop the following conditions: • A history of, increased risk for, or current arterial or venous thrombotic/thromboembolic ...
  • 5 WARNINGS AND PRECAUTIONS
    5.1 Thromboembolic Disorders and Other Vascular Problems - Stop FEMLYV if an arterial or deep venous thrombotic event (VTE) occurs. Stop FEMLYV if there is unexplained loss of vision ...
  • 6 ADVERSE REACTIONS
    The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling: • Serious cardiovascular events and stroke [see Boxed Warning and Warnings and Precautions ...
  • 7 DRUG INTERACTIONS
    7.1 Effects of Other Drugs on Combined Oral Contraceptives - Substances diminishing the efficacy of COCs: Drugs or herbal products that induce certain enzymes, including cytochrome P450 3A4 ...
  • 8 USE IN SPECIFIC POPULATIONS
    8.1 Pregnancy - Risk Summary - Discontinue FEMLYV if pregnancy occurs, because there is no reason to use hormonal contraceptives during pregnancy. Epidemiologic studies and meta-analyses have ...
  • 10 OVERDOSAGE
    Overdosage of CHCs may cause nausea, vomiting, and severe headaches. Individual reports of thromboembolic complications and vaginal bleeding have occurred from overdosage. Pediatric patients ...
  • 11 DESCRIPTION
    FEMLYV (norethindrone acetate and ethinyl estradiol orally disintegrating tablets) is a combined oral contraceptive. FEMLYV consists of 24 green, round ODTs each containing 1 mg norethindrone ...
  • 12 CLINICAL PHARMACOLOGY
    12.1 Mechanism of Action - CHCs lower the risk of becoming pregnant primarily by suppressing ovulation. 12.2 Pharmacodynamics - No specific pharmacodynamic studies were conducted with ...
  • 13 NONCLINICAL TOXICOLOGY
    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility - [See Warnings and Precautions (5.4, 5.5)].
  • 14 CLINICAL STUDIES
    The effectiveness of FEMLYV has been established for the prevention of pregnancy in females of reproductive potential based on adequate and well-controlled studies of norethindrone acetate/ethinyl ...
  • 16 HOW SUPPLIED/STORAGE AND HANDLING
    16.1 How Supplied - FEMLYV (norethindrone acetate and ethinyl estradiol orally disintegrating tablets), 1 mg/0.02 mg is available in a carton of three pouches, each pouch contains a blister card ...
  • 17 PATIENT COUNSELING INFORMATION
    Advise the patient to read the FDA-Approved patient labeling (Patient Information) Sexually Transmitted Infections - Advise females that FEMLYV does not protect against HIV infection or other ...
  • FDA-Approved Patient Labeling
    Guide for Using FEMLYV - WARNING TO WOMEN WHO SMOKE - Do not use FEMLYV if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side ...
  • PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – Carton Label
    FEMLYV™ (norethindrone acetate and ethinyl estradiol orally disintegrating tablets) 1mg/0.02mg - NDC Number 72495-601-84 - FEMLYV™ 28-day regimen - Each blister provides 24 days of active therapy - Rx ...
  • PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – Pouch Label
    NDC 72495-601-84 - FEMLYV™ (norethindrone acetate and ethinyl estradiol orally disintegrating tablets) 1mg/0.02mg - FEMLYV™ 28-day regimen - Each blister provides 24 days of active therapy - Rx ...
  • PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – Blister Card Label
    FEMLYV™ (norethindrone acetate and ethinyl estradiol orally disintegrating tablets) 1mg/0.02mg - RX only - Millicent Pharma®
  • PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – Sample Carton Label
    FEMLYV™ (norethindrone acetate and ethinyl estradiol orally disintegrating tablets) 1mg/0.02mg - NDC 72495-601-28 - Physician’s Sample – Not For Sale - FEMLYV™ 28-day regimen - Each blister provides 24 ...
  • PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – Sample Pouch Label
    NDC 72495-601-28 - FEMLYV™ (norethindrone acetate and ethinyl estradiol orally disintegrating tablets) 1mg/0.02mg - Physician’s Sample – Not For Sale - FEMLYV™ 28-day regimen - Each blister provides 24 ...
  • INGREDIENTS AND APPEARANCE
    Product Information